Aim: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. Patients & methods: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. Results: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes. Conclusion: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.
Eribulin in the treatment of advanced breast cancer: Real-world scenario from 39 Italian centers - ESEMPiO study / Barni, S.; Livraghi, L.; Morritti, M.; Vici, P.; Michelotti, A.; Cinieri, S.; Fontanella, C.; Musolino, A.; Porcu, L.; Del Mastro, L.; Puglisi, F. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 15:1(2019), pp. 3247-3258. [10.2217/fon-2018-0324]
Eribulin in the treatment of advanced breast cancer: Real-world scenario from 39 Italian centers - ESEMPiO study
Musolino A.;
2019-01-01
Abstract
Aim: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. Patients & methods: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. Results: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes. Conclusion: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
